# 10x Genomics account plan

> 10x Genomics sells single cell and spatial biology instruments, consumables and software; FY2025 revenue was $642.8 million.

## At a glance

10x Genomics is a life sciences tools company based in Pleasanton, California. It sells instruments, consumables and bundled software for single cell (Chromium) and spatial (Visium, Xenium, and since 2026 Atera) biology to academic, government, biopharma and biotech researchers in over 50 countries. FY2025 revenue was $642.8 million (+5%), net loss narrowed to $43.5 million, and the company had 1,178 employees at December 31, 2025. About 44% of revenue came from outside North America; it reports a single operating segment.

## Business units

- **Single Cell (Chromium)** (about 60% of FY2025 revenue): Chromium instruments with microfluidic chips and barcoded gel beads, plus consumables for gene expression, protein, chromatin, V(D)J and CRISPR readouts. FY2025 Single Cell consumables were $363.2 million (-2%) and instruments $22.7 million (-36%). Flex Apex, a lower-priced assay per reaction, is becoming the majority of reactions.
- **Spatial (Visium, Xenium, Atera)** (about 28% of FY2025 revenue): Visium maps whole-transcriptome expression across tissue sections; Xenium and the new Atera platform do in situ profiling. FY2025 Spatial consumables rose 19% to $144.0 million while instruments fell 41% to $34.1 million. Atera began shipping in September 2026.
- **Services** (about 5% of FY2025 revenue): Service plans for instruments coming off warranty; revenue rose 35% to $32.7 million in FY2025. Catalyst Research Services, the in-house lab, lets customers run samples on Atera.
- **License and royalty** (about 7% of FY2025 revenue): $46.1 million in FY2025, mostly non-recurring revenue from the Vizgen and Bruker patent settlements, plus ongoing royalties; it fell 93% to $3.3 million in the first nine months of 2026.

## Strategic priorities

- **Ramping the Atera spatial platform**: Atera shipped from late September 2026; the company now expects about 50 instruments shipped by year-end, up from about 40, and sees about 50 a quarter as the right rate going into 2027. Production, installation and training are the constraint, not demand.
- **Growing biopharma demand**: Nearly all of the world's top 20 biopharma companies have bought Atera systems or services through Catalyst Research Services, which had more than 100 customers book projects in 5 months. Flex Apex is scaling rapidly in biopharma.
- **AI and software**: Management calls AI a structural tailwind as large data-generation efforts aim to train models. The Sentira cloud analysis platform uses NVIDIA computing for spatial data and Anthropic's Claude for agentic single cell analysis.
- **Entering clinical markets**: Collaborations with Fred Hutch, Cleveland Clinic and Lausanne University Hospital in oncology, and an internal CLIA lab targeted for launch next year; today products are research use only.
- **Cost discipline**: A 2025 reduction in force cost about $10.6 million; R&D fell 10% and SG&A 8% in FY2025, and operating expenses excluding settlement gains are expected to modestly decrease in 2026.

## Latest results

In Q3 2026 (quarter ended September 30, 2026), revenue was $150.7 million, up 1% from $149.0 million. Consumables grew 5% to $134.3 million, with Spatial consumables up 16%, while instruments fell 43% to $6.9 million as customers held back Xenium and Visium purchases ahead of Atera. Gross margin rose to 75% from 67%, operating loss narrowed to $16.1 million and net loss was $19.4 million; cash and marketable securities were $575.7 million. FY2026 revenue guidance was raised to $625 million to $635 million, 4% to 6% growth excluding settlement revenue, with Q4 gross margin expected in the low to mid-60s.

## Investments and deals

- **Scale Biosciences acquisition**: Acquired in August 2025 for $9.2 million cash and $13.5 million in shares upfront, with a Q1 2026 milestone paid ($10.0 million cash and $8.7 million in shares) and up to $30.0 million contingent consideration; it adds QuantumScale kits.
- **Proteintech Genomics acquisition**: Bought on June 8, 2026 for $6.1 million in cash, with a 10-year supply agreement valued at $12.4 million, to add high-plex proteomics to Atera and Chromium.
- **Capital expenditure**: Capex planned at $10 million to $15 million over the next 12 months, per the Q3 2026 10-Q.
- **Patent enforcement**: 10x sued Illumina in October 2025 over spatial and single cell products, with trials scheduled for January 2028 and April 2028; Scale Bio won a jury verdict against Parse in August 2026.

## Challenges and risks

- **Academic funding pressure**: A substantial share of revenue depends on U.S. academic and NIH funding; the CEO describes the academic environment as one where the dollars are still not flowing out.
- **Atera transition risk**: Customers delayed Xenium and Visium purchases ahead of Atera; early units may show reliability issues, inventory could become excess, and 2027 margins are expected to be lower in an instrument-heavy year.
- **Price declines**: Average selling prices are expected to decline as lower-priced products such as Flex Apex grow, which puts pressure on top line revenue.
- **Trade and supply chain**: Exposure to U.S. tariffs and China trade tensions (China was about ten percent of 2025 revenue), single-source suppliers, and memory component prices that increased substantially during 2026.

## What leadership says

> "demand is not the bottleneck. We have lots and lots of orders" — Serge Saxonov, Co-Founder and Chief Executive Officer, Q3 2026 earnings call, November 2026

> "Atera is the future" — Serge Saxonov, Co-Founder and Chief Executive Officer, Q2 2026 earnings call, August 2026

> "AI is now a major structural tailwind for us" — Serge Saxonov, Co-Founder and Chief Executive Officer, Q2 2026 earnings call, August 2026

> "the overall gross margin profile of the Atera platform is superior to that of the Xenium platform" — Adam Taich, Chief Financial Officer, Q3 2026 earnings call, November 2026


## Where a supplier can help

- **Manufacturing and installation capacity**: Tied to the Atera ramp: production, installation and customer training are the stated constraint, so contract manufacturing, field service and training partners address the bottleneck directly.
- **AI compute and data partnerships**: Tied to the AI and software priority: cloud, compute and data-platform providers can support Sentira and the AI model-training customers 10x serves.
- **Clinical lab build-out**: Tied to the clinical-market priority: suppliers of CLIA lab equipment, quality systems and regulatory services can support the planned internal CLIA lab.
- **Supply chain resilience**: Tied to the trade and supply chain challenge: alternative sources for reagents, enzymes and memory components reduce single-source and tariff exposure.
- **Biopharma market access**: Tied to growing biopharma demand: partners with reach into biopharma research teams can help a company whose new Atera demand skews to biopharma as academic funding stays tight.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [10x Genomics Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1770787/000162828026007822/txg-20251231.htm)

Annual report · 2026-02-13

- 10x Genomics is a Pleasanton, California life sciences tools company selling instruments, consumables and software for single cell (Chromium) and spatial (Visium, Xenium) biology to academic, government and biopharma researchers; it operates as a single operating segment.
- FY2025 revenue was $642.8 million, up 5% from $610.8 million; products and services revenue fell 2% to $596.7 million while license and royalty revenue jumped to $46.1 million after the Vizgen and Bruker patent settlements.
- Consumables are the bulk of revenue: $507.2 million (+3%), with Spatial consumables up 19% to $144.0 million and Single Cell consumables down 2% to $363.2 million; instruments revenue fell 39% to $56.8 million on price decreases and lower Spatial volumes.
- Net loss narrowed to $43.5 million from $182.6 million; gross margin rose to 69%; operating cash flow was $136.1 million and cash plus marketable securities reached $523.4 million.
- 8,046 cumulative instruments sold (6,477 Chromium, 1,015 Visium, 554 Xenium) and 424,000 consumable reactions sold in 2025; sold in over 50 countries, about 44% of revenue from outside North America, China roughly ten percent of revenue.
- Cost discipline: a 2025 reduction in force cost about $10.6 million; R&D fell 10% and SG&A 8%; operating expenses (excluding settlement gains) and R&D are expected to modestly decrease in 2026.
- Growth bets: Scale Biosciences acquired in August 2025 (QuantumScale kits), a planned move into clinical markets, and a software ecosystem (Cell Ranger, Loupe Browser, Xenium Explorer); estimated TAM above $21 billion and SAM above $13 billion.
- Key risks: dependence on U.S. academic and NIH funding (including the 15% indirect cost cap), tariffs and China trade tensions, competition from sequencer makers, price declines, and single-source suppliers.

### [10x Genomics Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)](https://www.sec.gov/Archives/edgar/data/1770787/000162828026071199/txg-20260930.htm)

Interim report · 2026-11-06

- Q3 2026 revenue was $150.7 million, up 1% from $149.0 million; nine-month revenue fell 5% to $452.5 million because 2025 included $44.1 million of one-time settlement royalties.
- Consumables carried the quarter: $134.3 million (+5%), with Spatial consumables up 16% to $41.2 million and Single Cell consumables up 1% to $93.1 million.
- Instruments revenue fell 43% to $6.9 million (Spatial instruments -57%) as customers delayed Xenium and Visium purchases ahead of the new Atera platform, which began shipping in September 2026.
- Gross margin rose to 75% from 67% on lower inventory write-downs and mix; the company expects Q4 gross margin to decrease on product mix.
- Operating loss narrowed to $16.1 million and net loss to $19.4 million; cash and marketable securities were $575.7 million, up $52.3 million since December 2025.
- June 2026: acquired Proteintech Genomics for $6.1 million in cash plus a 10-year supply agreement, to expand proteomics on 10x platforms; a $6.7 million contingent-consideration loss followed Scale Bio's August 2026 jury win against Parse.
- Risks flagged: the Atera ramp (manufacturing, reliability, inventory), cannibalisation of Xenium and Visium, the single cell move to Flex Apex, rising memory component prices, and ongoing patent suits against Illumina.

### [10x Genomics Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/11/06/10x-genomics-txg-q3-2026-earnings-call-transcript/)

Executive talk · Serge Saxonov, Co-Founder and Chief Executive Officer (with Adam Taich, Chief Financial Officer) · 2026-11-05

- Q3 2026 revenue was $150.7 million (+1%); consumables grew 5%, Spatial consumables 16%, and gross margin reached 75%.
- Atera commercial shipments started in late September; the company now expects about 50 Atera instruments shipped by year-end, up from about 40, with only "a couple" in Q3 revenue.
- Saxonov: "demand is not the bottleneck"; production, installation and customer training are the binding constraints, and about 50 a quarter is "about the right number" going into 2027.
- Nearly all of the world's top 20 biopharma companies have bought Atera systems or services through Catalyst Research Services, which had more than 100 customers book projects in 5 months.
- FY2026 revenue guidance raised to $625 million to $635 million (from $610 million to $630 million), 4% to 6% growth excluding settlement revenue.
- Gross margin expected in the low to mid-60s in Q4, and 2027 margins likely lower in an instrument-heavy year, although Atera's margin profile is superior to Xenium's.
- AI is framed as a structural tailwind: Sentira cloud analysis launched, using NVIDIA computing for spatial data and Anthropic's Claude for agentic single cell analysis.
- Clinical strategy: new Fred Hutch collaboration, and an internal CLIA lab targeted for launch next year.

### [10x Genomics Q2 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/14/10x-genomics-txg-q2-2026-earnings-call-transcript/)

Executive talk · Serge Saxonov, Co-Founder and Chief Executive Officer (with Adam Taich, Chief Financial Officer) · 2026-08-06

- Q2 2026 revenue was $151 million; excluding $1.6 million of Takara settlement revenue it was $149.4 million, up 3%; consumables grew 7% and Spatial consumables 16%.
- Booked Atera orders at the end of Q2 "already greatly exceeded" the full-year plan of about 40 instruments; shipments stay at about 40, mostly in Q4, because manufacturing is the constraint.
- FY2026 guidance raised to $610 million to $630 million (2% to 5% growth excluding settlements), with a modest Q3 dip and a large Q4 step-up driven by Atera.
- Atera's maximum utilisation is about 2X Xenium's; Saxonov said the company did not need incentives to win orders and biopharma is a disproportionate buyer.
- Acquired Proteintech Genomics to add proteomics to Atera and Chromium ("the largest single-cell protein panels on the market").
- AI is "a major structural tailwind": most large data-generation efforts aim to train AI models, and most companies building virtual models of human biology use 10x technologies.
- Academic funding remains "tenuous"; guidance assumes the macro does not improve. New clinical partnerships with Cleveland Clinic and Lausanne University Hospital.

## Questions about 10x Genomics

### What does 10x Genomics do?

10x Genomics makes instruments, consumables and software that let researchers analyse biology at single-cell and spatial resolution, through its Chromium, Visium, Xenium and Atera platforms.

### What is 10x Genomics' revenue?

FY2025 revenue was $642.8 million, up 5%. FY2026 revenue is guided at $625 million to $635 million.

### How many employees does 10x Genomics have?

It had 1,178 employees at December 31, 2025, 822 of them in the U.S.

### Who leads 10x Genomics?

Co-founder Serge Saxonov is CEO and Adam Taich is CFO.

### What is Atera?

Atera is 10x Genomics' new spatial platform for whole transcriptome profiling at single cell sensitivity; it began shipping in September 2026, with about 50 instruments expected by year-end.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
